Mechanistically, our results indicate that the enhanced anti-tumor effects observed with gefitinib + G31P treatment are primarily due to inhibition of PI3K/AKT and MAPK/ERK pathways, which are central to EGFR-driven tumor growth [35]. This evidence concerns the gene AKT1 and neoplasm.